Carr Schultz, CEO of Teva (Flash 90, Sivan Farage)
Teva Pharmaceutical Industries Ltd., one of the largest and most important Israeli companies in the world, has increased its opioid addiction, a particularly powerful painkiller, in New York State, a jury ruled last night (Thursday). United States.
The ruling, which follows a nearly six-month trial in New York State Court in a case filed by the state and two of its counties, does not include compensation, which will be determined later. The jury debated more than eight days before reaching the verdict. Shares of Teva, which traded higher, fell more than 7 percent in New York following the decision. In afternoon trading, they were down 40 cents, or 4.7 percent, to $ 8.03.
More in-
The judge in the case is still considering a petition filed by Teva for misconduct after a state attorney cited inaccurate statistics regarding prescriptions for opioids in his closing argument. If the ruling is upheld, it could put pressure on Teva to reach a nationwide settlement with other states and local governments on opioid lawsuits.
Teva USA’s response, following the decision of the jury in New York: “Teva USA, a subsidiary of Teva Pharmaceutical Industries Ltd., strongly opposes the determination of the jury, and is preparing to file an appeal soon, in addition to its request to dismiss the proceedings, as “Filed before the jury convened to discuss the issue. In New York, prosecutors did not provide evidence of medically unnecessary prescriptions, suspicious or biased orders, no evidence of oversupply – or even an indication of adequate supply – and did not establish a causal link between marketing and harm.”
“As stated, prior to the jury’s hearing, Teva filed a motion to dismiss the proceeding in light of incorrect information provided by the State to the jury, which claimed that the amount of opioids distributed in New York was 500 times the amount actually taken. “Including access to opioids for approved medical uses. More importantly, the company continues to strive for a nationwide arrangement, for the benefit of patients who will directly benefit from finding an appropriate arrangement.”
“Just last month, a California court ruled that Teva did not cause public nuisance in the counties of Orange, Los Angeles, Santa Clara and the city of Auckland, and that Teva did not issue false or misleading statements regarding the marketing of opioid prescription products in California. The Oklahoma Supreme Court has earlier ruled against a drugmaker and ruled that the Oklahoma Public Harassment Act does not apply to the manufacture, marketing and sale of opioid prescription products.
Comments on the article(0):
Your response has been received and will be published subject to system policies.
Thanks.
For a new response
Your response was not sent due to a communication problem, please try again.
Return to comment